SCHEMBL6943675

SCHEMBL6943675

COC(=O)c1cc([N+](=O)[O-])ccc1N[C@H]1CC[C@@H](OC(C)=O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
KMT2A Q03164 2/20 0.47
YAP1 P46937 1/20 0.47
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46
SLC6A9 P48067 1/20 0.43
SLC6A5 Q9Y345 1/20 0.43
HTT P42858 2/20 0.43
PKM P14618 1/20 0.42
HCAR3 P49019 1/20 0.42
OPRK1 P41145 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943673 1.00 MAPT (0.48) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6941192 0.86 MAPT (0.52) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6940663 0.86 MAPT (0.52) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6939758 0.80 GABRP (0.48) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6939754 0.80 GABRP (0.48) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL7370553 0.79 YAP1 (0.45) YAP1
SCHEMBL7370214 0.79 YAP1 (0.45) YAP1
SCHEMBL6941197 0.77 MAPT (0.62) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6944865 0.77 MAPT (0.64) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL30780941 0.76 ALDH1A1 (0.49) MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPT 4706/4885NPSR1 2833/4885L3MBTL1 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.